Key result
Painful physical symptoms show no independent link to lower citalopram remission after adjusting for illness burden.
Why the study?
Whether painful physical symptoms significantly contribute to poorer treatment outcomes in major depressive disorder across primary and specialty psychiatric care settings remains unclear.
Does the presence of painful physical symptoms affect remission rates in out-patients with major depressive disorder treated with citalopram?
Cohort (n=2,876)
Yes
Does the presence of painful physical symptoms affect remission rates in out-patients with major depressive disorder treated with citalopram?
The presence of painful physical symptoms in MDD is associated with poorer treatment outcomes with citalopram, but this is driven by multifactorial demographic and clinical factors rather than the pain itself.
PPS mark MDD patients with lower citalopram remission that vanishes after confounder adjustment; leaves open whether pain signals multifactorial vulnerability rather than driving outcomes.
BACKGROUND: Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear. METHOD: Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS. RESULTS: Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes. CONCLUSIONS: Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.
No takes yet. Share an insight, caveat, or question.
Leuchter et al. (2009) conducted a cohort in Major depressive disorder (n=2,876). Painful physical symptoms (PPS) vs. Absence of painful physical symptoms was evaluated on Time to and overall rates of remission. Painful physical symptoms in MDD patients were associated with lower remission rates with citalopram, but this association was no longer significant after adjusting for illness burden and demographics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: